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Literature Review 
The fibroblast growth factor (FGF) signaling pathway comprises 18 ligands and 4 
FGF receptor (FGFR) subtypes, FGFR1, -2, -3, and -4, which are receptor-type tyrosine 
kinases. Upon ligand binding, FGFRs activate an array of downstream signaling 
pathways, such as the mitogen activated protein kinase (MAPK) and the 
phosphoinositide-3-kinase (PI3K)/Akt pathways (Dieci et al., 2013; Turner and Grose, 
2010).  
In cancer, FGFRs with genetic abnormalities (gene fusion, mutation, or 
amplification) activate their signaling pathways, which contribute to proliferation, 
survival, and migration of cancer cells, tumor angiogenesis, and drug resistance (Turner 
and Grose, 2010). These abnormalities have been reported to be involved in cancer types 
including lung cancer (Cancer Genome Atlas Research, 2012; Liao et al., 2013; Thomas 
et al., 2014; Wu et al., 2013), breast cancer (Andre and Cortes, 2015; Wu et al., 2013), 
multiple myeloma (Dieci et al., 2013), endometrial cancer (Byron et al., 2012), gastric 
cancer (Matsumoto et al., 2012), glioblastoma (Singh et al., 2012), cholangiocarcinoma 
(Arai et al., 2014), and urothelial cancer (Network, 2014; Williams et al., 2013; Wu et al., 
2013). Therefore, FGFRs are considered promising targets for cancer therapy, and FGFR 
inhibitors may serve as therapeutic agents. 
The most clinically advanced FGFR inhibitors are multi-target kinase inhibitors 
such as ponatinib, nintedanib, dovitinib, and lucitanib. These inhibitors suppress 
multiple tyrosine kinases, but FGFRs are not inhibited as strongly as other kinases such 
as vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor 
receptor (PDGFR), or ABL1 (Carter et al., 2015). Therefore, these inhibitors seem to be 
unlikely to achieve the required drug exposure for sufficient inhibition of the FGFR 
signaling pathway in tumors in a clinical setting.  
Recently, the field of FGFR targeting has progressed exponentially, and several 
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FGFR-selective inhibitors, such as AZD4547 (Gavine et al., 2012), NVP-BGJ398 
(Guagnano et al., 2011), and JNJ-42756493 (Tabernero et al., 2015), are in clinical trials, 
including some Phase 2 studies, targeting patients who have genetic alterations of 
FGFRs (Carter et al., 2015). Although these inhibitors produced partial responses in 
some cancer patients harboring FGFR gene abnormalities in Phase 1 studies, all of them 
are still under clinical development. Especially, the contribution of these inhibitors to 
prolongation of survival time remains to be clarified. Thus, there is a need to develop 
novel compounds that show potent FGFR inhibitory activity, suitable physicochemical 
property, pharmacokinetics profile, and the ability to prolong survival. 
 
Research Purpose and Objectives 
To provide a novel therapeutic option for cancer harboring FGFR abnormalities, a 
novel compound with potent and selective FGFRs inhibitor with suitable 
physicochemical property, pharmacokinetics profile, and the ability to prolong survival 
has been explored. Here, I report the preclinical pharmacological analyses of a novel 
selective FGFR inhibitor, E7090. It is an orally available tyrosine kinase inhibitor with 
a new type of binding kinetic profile to FGFR1. The analyses included target binding, 
antitumor activity in several subcutaneous human cancer cell line xenograft models, and 
survival benefit in a preclinical lung metastasis model. E7090 is currently being 
investigated in a Phase 1 study (NCT 02275910).  
 
 
Methods 
Compounds 
E7090, E7090 succinate, AZD4547, ponatinib, and PD173074 were synthesized at 
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Eisai Co. Ltd., in accordance with a previously reported procedures (Li et al., 2012; 
Thompson et al., 2005) and are described in patent publications WO 2014129477 (US 
20140235614), WO 2016027781, WO 2008075068, and WO 2007075869. For in vitro 
studies, all compounds were prepared as a 20 mmol/L stock solution in dimethyl 
sulfoxide (DMSO) and diluted in the relevant assay media. For in vivo studies, E7090 
was formulated in a 3.5% (v/v) DMSO/6.5% (v/v) Tween 80/5% (w/v) glucose solution, and 
the administration volume (0.2 mL/10 g body weight) was calculated from the body 
weight before administration. E7090 succinate was dissolved in distilled water and the 
administration volume (0.1 mL/10 g body weight) was calculated from the body weight 
before administration.  
 
Cell lines and reagents 
Cell lines were obtained from the American Type Culture Collection (from 1993 to 
2013), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (in 2009 and 
2010), European Collection of Authenticated Cell Cultures (from 2008 to 2012), Immuno-
Biological Laboratories Co., Ltd. (from 1990 to 2005), and Japanese Collection of 
Research Bioresources Cell Bank (in 2009 and in 2013). All cell lines were authenticated 
by the cell banks with short tandem repeat (STR) analysis from 2013 to 2016. 
Antibodies against phospho-FGFR (Tyr653/654), FGFR1, phospho-FRS2α(Tyr), 
phospho-ERK1/2 (Thr202/Tyr204), ERK1/2, phospho-AKT (Ser473), and AKT were 
obtained from Cell Signaling Technology. An antibody against FGFR2 was obtained from 
Santa Cruz Biotechnology. An antibody against β-actin was obtained from Sigma-Aldrich. 
Peroxidase-conjugated secondary antibodies were obtained from Cell Signaling 
Technology. 
 
Cell-free kinase inhibition assay 
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Inhibitory activities of E7090 against 93 purified recombinant protein kinases 
(including tyrosine kinases and serine threonine kinases) were examined by using an 
Off-Chip Mobility Shift Assay from Carna Biosciences, Inc.. Briefly, a DMSO solution of 
E7090 was mixed with enzyme, substrate, ATP, and metals such as magnesium, calcium, 
or manganese under appropriate buffer conditions for each protein kinases. The readout 
value of the reaction control (complete reaction mixture) was set as 0% inhibition, and 
the readout value of the background (in the absence of enzyme) was set as 100% 
inhibition; the percent inhibition of each test solution was then calculated. IC50 values 
(the half maximal inhibitory concentration) were calculated from plots of concentration 
versus percent inhibition by using Microsoft Excel or GraphPad Prism. 
 
Kinetic interaction analysis against FGFR1 
Experiments to determine the binding affinities and kinetic rate constants of 
interactions between compounds and FGFR1 were performed as described 
previously(Neumann et al., 2009; Neumann et al., 2011). Briefly, FGFR1 (final 
concentration 6.7 nmol/L) was preincubated with the reporter probe at a concentration 
equal to its binding affinity (Kd) in a reaction buffer consisting of 20 mmol/L 3-
Morpholinopropanesulfonic acid (MOPS) (pH 7.0), 1 mM Dithiothreitol (DTT), and 0.01% 
Tween20. The final reaction volume was 10 µl in black NBS 384-well polypropylene 
plates. After transfer of serially diluted compounds, probe displacement was monitored 
for 60 min. Kd values were calculated by using the Cheng-Prusoff equation from the IC50 
values obtained from the percentage displacement values at the last time point 
measured. Association rate constants of the inhibitors were calculated from the decay 
rate of probe displacement. Dissociation rate constants were determined as the product 
of Kd × association rate constant. 
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Cell proliferation assay 
Cells (500 to 5000) were seeded in a 96-well cell culture plate in RPMI-1640 (WAKO) 
containing 10% (v/v) fetal bovine serum (FBS) (Sigma-Aldrich). One day after cell 
seeding, various concentrations of compounds were added, and the cells were incubated 
at 37°C for 3 to 14 days. Then Cell Counting Kit-8 (Dojindo Laboratories) was added to 
each well, followed by incubation for the appropriate time. The optical density (OD) of 
each well was measured at 450 nm (reference wavelength: 650 nm) with a SpectraMax 
250 (Molecular Devices) or EnVision (Perkin Elmer) microplate reader. 
 
In vitro signal inhibition analysis 
SNU-16 cells were treated with the indicated concentrations of E7090 succinate in 
RPMI-1640 containing 10% FBS for 4 h and lysed with RIPA buffer (Sigma-Aldrich) 
containing protease and phosphatase inhibitors. The protein expression of the indicated 
proteins was detected by Western blot. The blots were developed with ECL Prime 
Western Blotting detection reagents (GE Healthcare), and chemiluminescence was 
detected with an Image Analyzer LAS-4000 (Fuji Film). The chemiluminescence 
intensity of each band was measured using Multi Gauge software (version 3.1, Fuji Film).  
The percentage of phosphorylation was determined by the following formula: 
p-FGFRs (% of control) = 100 × (T–Bt)/(C–Bc)  
where  
T is the chemiluminescence intensity of p-FGFRs in the drug-treated sample lane, 
Bt is the chemiluminescence intensity of background in the drug-treated sample lane, 
C is the chemiluminescence intensity of p-FGFRs in the control sample lane, and 
Bc is the chemiluminescence intensity of background in the control sample lane. 
 
7 
 
Knockdown experiments 
Small interfering RNAs (siRNAs) targeting mouse Fgfr1 (FGFR1 Stealth Select RNA 
interference [RNAi] MSS204294), mouse Fgfr2 (FGFR2 Stealth Select RNAi 
MSS204298), mouse Fgfr3 (FGFR3 Stealth Select RNAi MSS204301) and mouse Fgfr4 
(FGFR4 Stealth Select RNAi MSS236498), Stealth RNAi Negative Control med GC (as 
a control for siFGFR1, -2, -3) and Stealth RNAi Negative Control low GC (as a control 
for siFGFR4) were purchased from Thermo Scientific. Transfection complexes were 
prepared in antibiotic-free and serum-free medium by mixing 1 μM of siRNA solution 
(final concentration 3 nM) and DharmaFECT4 tranfection reagents (Thermo Scientific, 
final concentration 0.1 μL/well) in accordance with the manufacturer’s recommended 
protocol. Then 4T1 cells (500 cells/well) were incubated with transfection complexes for 
72 h, and the effect of cell growth was detected using Cell-Counting Kit-8. The optical 
density (OD) of each well was measured at 450 nm (reference wavelength: 650 nm) with 
EnVision™ (Perkin Elmer) microplate reader. The differences in OD450nm-OD650nm 
between the Negative control-treated and siFgfr1-4 groups were analyzed by one-way 
analysis of variance followed by the Dunnett multiple comparison test (more than 3 
groups; the Negative control vs siFgfr1, siFgfr2 and siFgfr3) or t-test (2 groups; the 
Negative control vs siFgfr4). A value of P < 0.05 (2 sided) was considered statistically 
significant. Statistical analyses were performed using GraphPad Prism. 
 
Mouse subcutaneous xenograft model 
Mice were maintained under specific-pathogen-free conditions and housed in barrier 
facilities on a 12 h light/dark cycle, with food and water ad libitum. Animal experiments 
were conducted in accordance with the Institutional Animal Care and Use Committee 
guidelines of Eisai Co., Ltd. 
Cultured human cancer cells were prepared in Hank's Balanced Salt Solution 
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(Thermo Fisher Scientific Inc.) and mixed with an equal volume of BD Matrigel (BD 
Bioscience) to yield a suspension of 3.6 × 107 to 9.0 × 107 cells/mL. A 0.1 mL aliquot of the 
cell suspension was transplanted subcutaneously into the right flank region of female 
nude mice (7 weeks old, CLEA Japan or Japan SLC). When tumor volumes reached 
around 100–300 mm3, mice were selected based on their tumor volumes and general 
condition, and were randomly divided into groups according to their tumor volumes 
(n = 4–6 per group). The oral administration of E7090 or E7090 succinate (6.25, 12.5, 25, 
or 50 mg/kg) or vehicle (control) was started on day 1, and the administration continued 
once daily for 11 to 14 days. The tumor was measured in two dimensions, and the volume 
was calculated using the following formula: tumor volume (mm3) = 1⁄2 length (mm) × 
[width (mm)]2. 
The differences in tumor volume between the vehicle-treated and E7090 or E7090 
succinate–treated groups were analyzed by one-way analysis of variance followed by the 
Dunnett multiple comparison test. A value of P < 0.05 (2 sided) was considered 
statistically significant. Statistical analyses were performed using GraphPad Prism. 
SNU-16 tumors and plasma samples were collected at the indicated times after 
single oral administration. Nude mice bearing SNU-16 tumors were prepared as 
described above. Mice were given vehicle (n = 5) or indicated doses of E7090 (n = 3 per 
group) orally, and blood samples and tumors were collected at the indicated times. 
Plasma concentrations of E7090 were determined by liquid chromatography-tandem 
mass spectrometry (LC-MS/MS). In short, plasma samples and standards were 
deproteinized with methanol-acetonitrile (3:7 [v/v]) containing an internal standard and 
centrifuged. The supernatant was then filtered and analyzed by LC-MS/MS. 
For signal inhibition analysis, tumors were homogenized and lysed with Cell Lysis 
Buffer (Cell Signaling Technology) containing protease and phosphatase inhibitors. The 
protein expression of the indicated proteins was detected and the band intensity was 
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measured as described above. The ratio of phosphorylated FGFRs to total FGFR2 was 
calculated for each sample. Then the percentage of phosphorylation was determined by 
the following formula: 
p-FGFRs/FGFR2 (% of control) = 100 × T’/C’  
where  
T’ is the ratio of p-FGFRs/FGFR2 for the drug-treated sample lane, and 
C’ is the ratio of p-FGFRs/FGFR2 for the control sample lane. 
 
Plasma FGF23 measurement 
Nude mice bearing SNU-16 tumors were prepared as described above and 
administered vehicle (n = 5) or the indicated doses of E7090 (n = 3 per group) orally. 
Twenty-four hours later, plasma was collected, and the amount of plasma FGF23 was 
measured by using an FGF23 ELISA kit (Kainos Laboratories) in accordance with the 
manufacturer’s procedure.  
The differences in the amount of FGF23 between the vehicle-treated and E7090–
treated groups were analyzed by one-way analysis of variance followed by the Dunnett 
multiple comparison test. A value of P < 0.05 (2 sided) was considered statistically 
significant. Statistical analyses were performed using GraphPad Prism. 
 
4T1 lung metastasis model 
The 4T1 lung metastasis mouse model was established as previously reported (Dey 
et al., 2010) with some modification. Briefly, 5 × 104 4T1 cells were injected into the tail 
veins of female Balb/c mice (8 weeks old, Charles River Japan). Eleven days after the cell 
injection, the mice were randomly divided into groups (n = 8 per group) and treated with 
vehicle or various concentrations of E7090 (orally, once daily). Mice were sacrificed 
according to the guideline for animal experiment of Eisai Co., Ltd. 
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Survival times between the E7090-treated group and the vehicle-treated group were 
compared with the log-rank (Mantel-Cox) test. Values of P < 0.01 were considered 
statistically significant. Statistical analyses were performed using GraphPad Prism. 
 
Results 
E7090 shows selective inhibition of FGFR tyrosine kinases 1-3 
E7090, 5-({2-[({4-[1-(2-Hydroxyethyl)piperidin-4-yl]phenyl}carbonyl)amino]pyridin-
4-yl}oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide, was synthesized as 
an orally available and selective inhibitor of FGFR1, -2, and -3. The structure of E7090 
succinate is shown in Figure 1A. In this research, either E7090 or E7090 succinate was 
used in each study. To evaluate the selectivity of E7090 against FGFR1, -2, and -3, a 
kinase inhibition assay against 93 kinases, including wild-type and mutated members 
of the FGFR family, other receptor tyrosine kinases, and serine/threonine kinases was 
performed (Figure 1B and Supplementary Table S1). The IC50 values of E7090 on the 
enzymatic activity of FGFR1, -2, -3, and -4 were 0.71, 0.50, 1.2, and 120 nmol/L, 
respectively. The IC50 values of E7090 against mutated forms of FGFR3 (K650E and 
K650M) were 3.1 and 16 nmol/L, respectively. In addition, E7090 inhibited only 3 
additional tyrosine kinases (RET, DDR2, and FLT1) with IC50 values lower than 10 
nmol/L among the 93 kinases. A kinome map is shown in Supplementary Figure S1. 
These results indicate that E7090 is a selective inhibitor against FGFR1, -2, and -3 
tyrosine kinases. 
 
The interaction of E7090 with FGFR1 kinase possesses unique kinetics  
To gain insight into the mode of interaction between E7090 succinate and FGFR1, 
the kinetics of the interaction was analyzed by using the Proteros reporter displacement 
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assay (Okamoto et al., 2015). The kinetic parameters for the interactions of FGFR1 with 
AZD4547 and ponatinib, which, from their co-crystal structures, are representative type 
I and type II FGFR1 inhibitors, respectively (Tucker et al., 2014) were also determined. 
The kon and koff values of E7090 succinate were 3.4 × 105 s-1 M-1 and 8.6 × 10-4 s-1, 
resulting in a Kd value of 2.5 nmol/L (Table 1). The kinetic parameters for the 
interactions of AZD4547 and ponatinib with FGFR1 were consistent with the reported 
features of the interaction modes of these inhibitors (Tucker et al., 2014). Ponatinib had 
relatively slow association and dissociation kinetics, with a residence time of 57 min. In 
contrast, AZD4547 had fast association and dissociation kinetics, with a residence time 
of 7 min. E7090 succinate had interaction kinetics with FGFR1 kinases intermediate 
between those of the two representative inhibitors, and the residence time of E7090 
succinate was 19 min. These data suggest that the interaction of E7090 with FGFR1 
possesses unique kinetics among selective FGFR inhibitors, similar to that of type V 
inhibitors (Okamoto et al., 2015). 
 
E7090 inhibits phosphorylation of FGFR and cell proliferation of SNU-16 
cells 
To evaluate the inhibitory activity of E7090 on the cellular FGFR signaling pathway, 
SNU-16 cells were treated with the indicated concentrations of E7090 succinate, and cell 
lysates were prepared for Western blotting analysis. SNU-16 is a human gastric cancer 
cell line which contains high copy numbers of FGFR2 and high levels of FGFR2 protein 
expression and tyrosine phosphorylation (Kunii et al., 2008; Xie et al., 2013). E7090 
succinate inhibited FGFR phosphorylation with an IC50 value of 1.2 nmol/L (Figure 2). 
E7090 treatment also inhibited the phosphorylation of FRS2α, ERK1/2, and AKT, 
molecules downstream of FGFRs, in a dose-dependent manner (Supplementary Figure 
S2). E7090 succinate inhibited SNU-16 cell proliferation with an IC50 value of 5.7 nmol/L 
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(Figure 3A), in a good agreement with the in vitro inhibition of FGFR phosphorylation. 
 
E7090 has selective anti-proliferative activity against cancer cell lines 
harboring FGFR abnormalities 
E7090 was tested on a panel of 39 human cancer cell lines in cell proliferation assays 
(Supplementary Table S2). The IC50 values observed ranged from 2 nmol/L to greater 
than 10,000 nmol/L (Figure 3B). Thirteen cell lines were highly sensitive to E7090, with 
IC50 values less than 100 nmol/L. In this group of cell lines, 12 of the 13 cell lines 
harbored an FGFR abnormality, including FGFR1 and/or FGFR2 amplification, FGFR1 
fusion, FGFR2 mutation, FGFR3 mutation, or FGFR3 fusion. These data indicate that 
E7090 has selective anti-proliferative activity against cancer cell lines harboring FGFR 
genetic abnormalities. 
 
E7090 has antitumor activity and inhibits FGFR signaling in a mouse 
xenograft model of SNU-16 human gastric cancer  
Next, the in vivo characteristics of E7090 were investigated in a SNU-16 
subcutaneous xenograft model. Nude mice bearing SNU-16 xenografts were orally 
treated with various concentrations of E7090 succinate once daily for 14 days. 
Administration of 6.25 to 50 mg/kg E7090 succinate significantly inhibited tumor growth 
(Figure 4A) without severe loss of body weight (Figure 4B). To confirm the selective 
antitumor activity of E7090 against tumors harboring FGFR gene abnormalities in vivo, 
additional in vivo experiments using several human cancer cell lines were performed 
(Table 2). E7090 also had dose-dependent antitumor activity against other xenograft 
tumors harboring FGFR abnormalities such as FGFRs amplifications or fusions (NCI-
H1581, DMS114, RT112/84 or MFM223), whereas even a dose of 50 mg/kg E7090 lacked 
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antitumor activity against xenograft tumors with no FGFR abnormalities (MCF-7, 
HCC1806, HCC1427, or MDA-MB-468). These data indicate that E7090 has selective 
anti-tumor activity against xenograft tumors harboring FGFR genetic abnormalities 
such as amplifications or fusions. 
Next, a pharmacodynamic analysis of the level of FGFR phosphorylation in tumors 
in nude mice bearing SNU-16 tumors was performed. FGFR phosphorylation was 
inhibited by E7090 in a dose-dependent and time-dependent manner as assessed in a 
Western blotting analysis. E7090 at doses of 6.25 to 50 mg/kg reduced phosphorylation 
of FGFR to less than 10% of control levels at 4 h after oral administration (Figure 5A 
and Supplementary Figure S3), after which the level of FGFR phosphorylation recovered 
to the control level by 24 h. In the 50 mg/kg dosing group, maximal inhibition of FGFR 
phosphorylation lasted for 12 h after drug administration. The effect of E7090 on plasma 
FGF23 level was also examined. FGF23 belongs to a subgroup of FGF ligands that 
function as endocrine factors, and elevation of plasma FGF23 has been demonstrated to 
be a surrogate pharmacodynamic biomarker of FGFR inhibition in both nonclinical and 
clinical studies (Kim et al., 2011; Wohrle et al., 2011). Dose-dependent elevation of 
plasma FGF23 was observed at 24 h after drug administration (Figure 5B). 
In addition, a pharmacokinetic analysis of E7090 in nude mice bearing SNU-16 
tumors was conducted. E7090 showed dose-dependent increase of maximum 
concentration (Cmax) and area under the curve (AUC) (Cmax values of 9.31, 23.8, 94.2, 
179.7, and 415 ng/mL and AUC values of 27.5, 84.4, 228.5, 481.6 and 1172.6 ng· h/mL 
for 3.13, 6.25, 12.5, 25, and 50 mg/kg, respectively; Figure 5C). 
 
E7090 treatment prolongs survival in a 4T1 mouse lung metastasis model 
To evaluate the effect of E7090 on survival, we established a lung metastasis model 
using 4T1, a mouse breast cancer cell line, in Balb/c mice as a clinically relevant model. 
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E7090 inhibited tumor growth of 4T1 with an IC50 value of 22 nmol/L in vitro (Figure 
6A). A siRNA knockdown experiment revealed that each Fgfr2 siRNA or Fgfr3 siRNA 
decreased cell growth of 4T1 cell, meaning that 4T1 cell growth is dependent on both 
FGFR2 and the FGFR3 signaling pathway (Supplementary Figure S4). The dependency 
of 4T1 cell growth on the FGFR signaling pathway was also confirmed by performing a 
cell proliferation assay using PD173074 (Figure 6A), another FGFR1, -2, and -3 inhibitor 
that has previously shown selective inhibitory activity against FGFR kinase in 
preclinical experiments (Mohammadi et al., 1998). Next, a challenge experiment was 
performed (Figure 6B). Cultured 4T1 cells were intravenously injected into mice, and 11 
days after cell inoculation, engraftment of 4T1 cells was observed in the lung. On the day 
engraftment was observed, administration of E7090 was started. In this model, mice 
became moribund within 20 days, suffering from cancer-induced cachexia and 
pulmonary dysfunction. Daily administration of E7090 significantly prolonged the 
survival of mice in the 12.5 to 50 mg/kg dosing groups (Figure 6C and Table 3).  
 
Discussion 
We have developed E7090, an orally available selective inhibitor of the FGFR1, -2, 
and -3 tyrosine kinases with a unique kinetic profile among FGFR inhibitors. E7090 
inhibited SNU-16 cell proliferation as expected from its in vitro inhibition of FGFR 
phosphorylation. E7090 shows selective anti-proliferative activity against cancer cell 
lines harboring FGFR abnormalities and showed antitumor activity in mouse 
subcutaneous xenograft models using cell lines with dysregulated FGFR signaling. 
Furthermore, E7090 administration significantly prolonged the lives of mice with lung 
metastases. Thus, E7090 is a selective FGFR inhibitor that shows promising antitumor 
activities with wide therapeutic windows in preclinical models of cancers harboring 
FGFR abnormalities. 
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Some multi-kinase inhibitors, including several FGFR-selective inhibitors and 
subtype-specific inhibitors, have been developed and are in clinical studies. Although 
some cancer patients harboring FGFR abnormalities have had partial responses in these 
clinical studies, none of them have exhibited any defined proof of concept in clinical 
studies. I present the first evidence that the interaction of E7090 with FGFR1 has unique 
kinetics that is different from those of other selective FGFR inhibitors. More than 80% 
of approved kinase inhibitors possess the characteristics of either type I inhibitors or 
type II inhibitors (Wu et al., 2016). Selective FGFR inhibitors such as AZD4547 have 
been reported to possess the characteristics of type I inhibitors. Generally, type I 
inhibitors have more rapid association and dissociation kinetics, whereas type II 
inhibitors such as ponatinib have slow binding kinetics, leading to a prolonged residence 
time (Liu and Gray, 2006; Tummino and Copeland, 2008). E7090 succinate associated 
more rapidly with FGFR1 than did ponatinib and E7090 dissociated more slowly and 
had a relatively longer resident time, than did AZD4547, which is a representative type 
I inhibitor. Our analysis revealed that E7090 possesses kinetic properties more similar 
to 4the type V inhibitors, such as lenvatinib, a VEGFR and multiple receptor tyrosine 
kinase inhibitor, which is the only type V kinase inhibitor approved for clinical use at 
this time (Wu et al., 2016). Further studies, including crystallization and co-structural 
determination of the FGFR1–E7090 complexes, are required to fully understand the 
details of E7090 binding to FGFRs at the amino acid level. In addition, the relationship 
between the unique binding kinetics of E7090 and its efficacy should be explored. For 
instance, mutations in the gatekeeper residues in kinase domain, which was known to 
cause the activation of tyrosine kinases, such as T790M in EGFR and T315I mutation in 
BCR-ABL were reported to induce conformational change of these protein structures and 
resistance against EGFR inhibitors erlotinib and gefitinib, and BCR-ABL inhibitor 
imatinib, respectively(Branford et al., 2002; Sutto and Gervasio, 2013; Yun et al., 2008; 
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Zhou et al., 2007). Similarly, mutation of the gatekeeper residue V561M in FGFR1 has 
been shown to confer in vitro drug resistance to FGFR inhibitors (Chell et al., 2013; Sohl 
et al., 2015). In addition, each N550H/K/S/T, E566A/G and K642N mutation in FGFR2 
kinase domain is reported to induce dovitinib-resistance. These amino acid residues are 
part of a triad that forms a network of autoinhibitory hydrogen bonds termed the 
molecular brake and these mutations disrupt this molecular brake in the kinase hinge 
region of FGFR2(Byron et al., 2013). FGFR2 mutants at N550 and K642 have been 
reported in adenoid cystic carcinoma, breast cancer, endometrial cancer, head and neck 
cancer, gallbladder cancer, and spermatocytic seminoma(Gallo et al., 2015). From these 
reports, it is also hypothesized that differences of binding kinetics among FGFR 
inhibitors may affect inhibitory activity of each compounds against mutated type of 
FGFRs. In this article, I could not fully determine the inhibitory activity of E7090 against 
mutated type of FGFRs which have been reported in various cancers. Now, evaluation of 
inhibitory activity of E7090 against mutated type of FGFRs is on-going by using several 
transformants which have representative FGFR mutation and human cancer cell lines 
harboring FGFR mutations. 
E7090 had selective anti-proliferative activity against cancer cell lines harboring 
FGFR abnormalities, but not all cell lines with these abnormalities were sensitive to 
E7090. One of the reasons is the protein expression level of FGFRs. In fact, some lung 
and breast cancer cell lines reported to have high copy numbers of FGFR1(Dutt et al., 
2011; Turner et al., 2010; Weiss et al., 2010) were not sensitive to E7090, and I confirmed 
by Western blotting analysis that these cell lines in fact expressed low levels of FGFR1 
(Supplementary Figure S5 and data not shown) (Kotani et al., 2016). Consistent with 
our results, J82, a human bladder cancer cell line harboring an FGFR3 K652E mutation, 
has been reported to be insensitive to FGFR inhibitors due to low protein expression 
(Lamont et al., 2011). Another reason may be activation of other signaling pathways, 
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which reduce activity of the FGFR inhibitor. Amplification of PDGFRA was also found 
in NCI-H1703 (Ramos et al., 2009). KRAS and RTK alterations occurred in a near 
mutually exclusive pattern, but PIK3CA, PTEN alterations, and FGFR alterations 
overlapped in patients with lung squamous carcinoma (Cancer Genome Atlas Research, 
2012) and endometrial cancer (Byron et al., 2012). In squamous cell lung cancer, MYC 
was co-expressed in about 40% of FGFR1-amplified tumors, and this co-expression was 
associated with sensitivity to FGFR inhibitors (Malchers et al., 2014). These results 
suggest that in addition to the presence of FGFR abnormalities, the expression level of 
FGFRs or the status of other molecules should be investigated to select patients suitable 
for treatment with E7090. 
E7090 showed antitumor activity in SNU-16 subcutaneous xenograft models in a 
dose-dependent manner without inducing severe weight loss. The Cmax value at a dose 
of 50 mg/kg, which is maximum tolerated dose (MTD) of E7090 in mice, is 415 ng/mL. 
The unbound Cmax value is calculated to be 12.5 ng/mL with unbound fraction in plasma 
(fu, 0.03), which is equivalent to 21.2 nmol/L. This result supports that there were few 
off-target effects even at the Cmax of the MTD dose. I also confirmed the mRNA 
expression level of FGFR2 was more than 500-fold higher than those of FLT-1, RET, 
DDR2, FLT-4, PDGFRA and KDR, which E7090 showed inhibitory activity with IC50 
values of lower than 20 nmol/L in cell-free kinase assay, in SNU-16 cells by using data 
extracted from the Cancer Cell Line Encyclopedia (CCLE) database (Barretina et al., 
2012) (Data not shown). Combined with these data, I propose that antitumor activity of 
E7090 in SNU-16 sc xenograft model is based on inhibition of FGFR signaling and the 
possibility that inhibition of other targets involved in its activity in this model is low. 
Administration of E7090 produced dose-dependent increases of Cmax and AUC and 
sustained inhibition of FGFR phosphorylation in SNU-16 tumors, suggesting that the 
level of phosphorylated FGFRs would be an appropriate pharmacodynamic marker of 
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target inhibition by E7090. In addition, E7090 administration also elevated plasma 
FGF23 levels in a dose-dependent manner 24 h after administration, suggesting that 
plasma FGF23 is a good candidate biomarker for non-invasive estimation of target 
inhibition in humans. The dose dependent inhibition of tumor growth, FGFR 
phosphorylation and FGF23 elevation were consistent with the plasma exposure. 
Yamazaki et al., reported an excellent example of Pharmacokinetic/Pharmacodynamic 
(PK/PD) modeling using crizotinib, an orally available, ATP-competitive dual inhibitor 
for ALK and MET. They characterized the PK/PD relationships among crizotinib 
systemic concentration, ALK or MET inhibition, and tumor growth inhibition in human 
tumor xenograft models in a quantitative manner and have produced clinically 
applicable results (Yamazaki et al., 2012). Therefore, PK/PD modeling would be thought 
to be a useful approach linking drug exposure to pharmacologic responses as a function 
of time, providing a quantitative assessment of in vivo drug potency with mechanistic 
insight of drug action. We will investigate the relationship between the pharmacokinetic 
data and pharmacodynamic changes observed in the current study, such as 
phosphorylation of FGFR in tumors and increased plasma FGF23 levels, in preclinical 
models as a method to predict human dosing in near future. 
In the setting of a clinical study, the survival benefit to patients is one of the most 
important endpoints for a new cancer therapeutic agent. Here, a mouse lung metastasis 
model was used to evaluate the effect of E7090 on survival. E7090 significantly prolonged 
the lives of mice in a dose-dependent manner. In this model, drug administration was 
started when 4T1 tumors grew in the lung 11 days after tumor cells were injected into 
the tail veins. This means that E7090 could be effective for metastases as well as primary 
lesions. However, even in the 50 mg/kg dosing group the mice became moribund and 
were euthanized. Further analysis of the residual tumors in the lung may help us to 
understand the mechanism of resistance and allow us to explore suitable drugs for use 
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in combination with E7090. 
In this article, I mainly focused on antitumor activity of E7090 against cancer cells 
harboring FGFR gene abnormality. In addition to FGFRs gene alteration, FGF-FGFR 
autocrine/paracrine signaling in tumors is also known to be important in various cancer 
malignancy such as migration/invasion and metastasis. FGF-2 was reported to cause 
sustained activation of the MAPK-ERK pathway, leading to MMP-9 gene transcription 
and cellular invasion in the presence of N-cadherin and cancer cells acquire metastatic 
properties in breast cancer cells(Suyama et al., 2002). In regard with anti-metastatic 
activity, 4T1 lung metastasis model used in Figure 6B&C can’t reflect process of cancer 
metastasis because tumor formation at lung has been completed at the timing of drug 
administration. To confirm the inhibitory activity of E7090 against metastasis, using 
other models, like 4T1 fat pad injection model or percutaneous injection model (Bailey-
Downs et al., 2014; Rashid et al., 2014) should be needed. 
To maximize antitumor effect of compounds, it is important to pay attention not only 
cancer cells but tumor microenvironment components such as and stromal/immune cells. 
In tumor microenvironment, several cancer cells release pro-fibrotic FGFs that act on 
cancer-associated fibroblasts (CAFs) and induce their activation; in turn, CAF-produced 
FGFs actively sustain growth and invasion of FGFRs-expressed tumors (Procopio et al., 
2015). FGF2 is also reported to have a key role in wound healing and angiogenesis by 
promoting proliferation and migration of endothelial cells in murine models, particularly 
in combination with vascular endothelial growth factor (VEGF) (Ichikawa K and et al., 
2016; WERNER and GROSE, 2003). In this article, the effect of E7090 against tumor 
microenvironment such as tumor vasculature or stroma cells etc. has not been clarified. 
Therefore, to find out the efficacy of E7090 as the modulator of tumor microenvironment, 
additional exploratory experiments are required.  
In summary, I propose that E7090 could be a novel therapeutic agent for cancer 
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patients with abnormalities in the FGF/FGFR signaling pathway. Based on the 
preclinical results reported here, E7090 is currently being investigated in a Phase 1 
clinical trial (NCT 02275910). 
 
Conclusion 
From these results, E7090 is clarified as a potent and selective FGFR1, 2 and 3 
inhibitor showing antitumor activities in preclinical cancer models harboring FGFRs 
gene abnormalities and prolongation of survival in mice model. E7090 is also found to 
show a new type of binding kinetics to FGFR1 with fast association and slow dissociation. 
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Table 1. Parameters of kinetic interactions with FGFR1. 
 
IC
50
 
(nmol/L) 
Kd (nmol/L) Kon (s
-1
× M
-1
) Koff (s
-1
) Residence 
time 
(min) 
E7090 
succinate 
5.00 ± 0.15 2.50 ± 0.08 3.43 × 10
5
 
± 4.78 ×10
4
 
8.57 × 10
-4
 
± 1.45 × 10
-4
 
19 ± 3 
AZD4547 6.02 ± 0.22 3.01 ± 0.11 7.51 × 10
5
 
± 1.19 × 10
5
 
2.26 × 10
-3
 
± 4.43 × 10
-4
 
7 ± 1 
Ponatinib 22.4 ± 1.30 11.2 ± 0.65 2.62 × 10
4
 
± 1.11 × 10
3
 
2.93 × 10
-4
 
± 2.93 × 10
-5
 
57 ± 6 
Kd = 1/2 × IC50, Koff = KD × Kon, residence time = 1/Koff 
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Table 2 
Antitumor activity of E7090 or E7090 succinate in various mouse models implanted with 
human cancer cell lines. 
NT: not tested, #:E7090 succinate data, *:P < 0.05 (Dunnett test vs vehicle at last dosing 
day) 
  
Cell line Tissue FGFRs abnormality 
Dosing 
duration 
(days) 
⊿ T/C (%) 
6.25 
mg/kg 
12.5 
mg/kg 
25 mg/kg 50 mg/kg 
SNU-16# Gastric 
FGFR2 
amplification 
14 51* 26* 13* 0* 
NCI-H1581# Lung 
FGFR1 
amplification 
14 37* 17* 5* 1* 
DMS114 Lung 
FGFR1 
amplification 
14 NT 61 44* 38* 
RT112/84 Bladder 
FGFR3-TACC3 
fusion 
14 48 61 41 -5* 
MFM223# Breast 
FGFR1&2 
amplification 
12 NT -2* NT -42* 
HCC1806# Breast None 11 NT NT NT 93 
MCF7# Breast None 14 NT NT NT 104 
HCC1428# Breast None 14 NT NT NT 103 
MDA-MB-468# Breast None 14 NT NT NT 97 
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Table 3. Median survival time of each treated group in 4T1 lung metastasis model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* P < 0.05 compared with vehicle-treated mice (Log-rank (Mantel-Cox) test) 
 
 
 
Median 
Survival 
Time (days) 
Survival 
(% of 
control) 
P value 
Vehicle 19 100  
6.25 mg/kg 22 116 0.0797 
12.5 mg/kg 23 121* 0.0018 
25 mg/kg 29 150* <0.0001 
50 mg/kg 34 176* <0.0001 
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Figure 1. The chemical structure of E7090 succinate and the selectivity against 93 
kinases with E7090.  
A, Chemical structure of E7090 succinate, 5-({2-[({4-[1-(2-Hydroxyethyl)piperidin-4-
yl]phenyl}carbonyl)amino]pyridin-4-yl}oxy)-6-(2-methoxyethoxy)-N-methyl-1H-
indole-1-carboxamide butanedioate (2:3). 
B, IC50 values for the inhibition by E7090 of 93 human kinases. Bars that indicate 
wild-type or mutated FGFR1, -2, or -3 are shown in red. See Supplementary Table S1 
for the full list. 
 
A 
B 
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Figure 2. Inhibition of FGFRs phosphorylation by E7090 in human gastric cancer cell line 
SNU-16. 
Effect of E7090 succinate on phosphorylation of FGFR in SNU-16 cells. Cells were treated 
for 4 h, and whole-cell lysates were analyzed by Western blotting with antibodies to 
phospho-FGFR (p-FGFR; Y653/654) or FGFR2. Band intensity was quantified and the IC50 
value was calculated. Data are shown as mean  SD (n = 3). 
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Figure 3. Inhibition of cell proliferation by E7090 in human cancer cell lines. 
A, SNU-16 cells were incubated with the indicated concentrations of E7090 succinate 
for 72 h, and IC50 values were calculated. Data are shown as mean  SD (n = 3). 
B, Cells were treated with various concentrations of E7090 and cell growth was 
measured by Cell Counting Kit-8. Cell lines are shown in order of IC50 values and 
categorized by FGFR gene alterations. Detailed information, including IC50 value and 
incubation time, is shown in Supplementary Table S2. 
 
A 
B 
27 
 
  
 
Figure 4. Inhibition of tumor growth in SNU-16 xenograft model by administration of 
E7090. 
Nude mice bearing SNU-16 xenografts were treated orally once daily for 14 days with 
either vehicle or E7090 succinate at the indicated doses.  
A, Tumor volume. Data are shown as mean  SD (n = 6). ***, P < 0.001, ****, P < 0.0001 
compared with vehicle-treated mice (Dunnett test). 
B, Body weight measurements during the treatment. Data are shown as mean  SD (n 
= 6). 
A 
B 
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  Figure 5. Inhibition of FGFR signaling in SNU-16 xenograft model by administration 
of E7090. 
A, Pharmacodynamic analysis of E7090 in mice bearing SNU-16 tumors. E7090 was 
orally administered at the indicated doses, and blood and tumors were collected at 
the indicated time points. The percentage of FGFR2 phosphorylation compared with 
vehicle is plotted. Data are shown as mean  SD (E7090: n = 3; vehicle: n = 5). 
Western blotting data for each sample against FGFR2 or phospho-FGFR (Y653/654) 
are also shown in Supplementary Figure S3. 
B. Plasma FGF23 level 24 h after administration of E7090 or vehicle (control). FGF23 
concentrations were determined by ELISA from plasma. Data are shown as mean  
SD. *, P < 0.05 compared with vehicle-treated mice (Dunnett test). 
C, Pharmacokinetic analysis of E7090 in mice bearing SNU-16 tumors. E7090 was 
orally administered at the indicated doses, and blood and tumors were collected at 
the indicated time points. E7090 concentration in plasma is plotted. 
 
A B 
C 
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Figure 6. Prolonged survival with daily E7090 administration in a mouse 4T1 lung 
metastasis model. 
A. Both E7090 and PD173074 show inhibitory activity against the growth of 4T1 
cells. 4T1 cells were incubated with the indicated concentrations of E7090 or 
PD173074 for 72 h. Data are presented as mean  SD (n = 3). 
B. Experimental plan for the 4T1 lung metastasis model.  
C. Survival curve of 4T1 lung metastasis model. Cultured 4T1 cells were inoculated 
intravenously into Balb/c mice on day 0. Daily administration with either vehicle or 
E7090 was started on day 11. Each group comprised 8 mice.  
 
C 
D 
B A 
C 
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Supplementary information 
Supplementary Table S1 
IC50 values for the inhibition of 93 human kinases by E7090. 
kinase IC
50
 
(nmol/L) 
kinase IC
50
 
(nmol/L) 
kinase IC
50
 
(nmol/L) 
kinase IC
50
 
(nmol/L) 
FGFR1 0.71 FRK 340 INSR >10000 Erk2 >10000 
FGFR2 0.50 HER4 1000 JAK2 >10000 GSK3β >10000 
FGFR3 1.2 BRK 1200 KIT(D816V) >10000 IKKβ >10000 
FGFR4 120 BRAF(V600E)_Cascade 1800 KIT(T670I) >10000 IRAK4 >10000 
FGFR3(K650E) 3.1 SRC 1900 MET >10000 JNK2 >10000 
FGFR3(K650M) 16 EPHA1 2000 MUSK >10000 MAPKAPK2 >10000 
FGFR4(N535K) 88 EPHB2 2100 ROS >10000 MST1 >10000 
FGFR4(V550E) >10000 CSK 2600 SYK >10000 NEK2 >10000 
FGFR4(V550L) >10000 PDGFRα(T674I) 2700 TRKB >10000 p70S6K >10000 
RET 3.9 p38α 2800 AKT1 >10000 PAK2 >10000 
DDR2 4.7 RAF1_Cascade 2900 AMPKα1/β1/γ1 >10000 PBK >10000 
FLT1 4.9 HGK 3700 AurA >10000 PDK1 >10000 
RET(M918T) 15 TIE2 4100 BRAF_Cascade >10000 PIM1 >10000 
PDGFRα 15 EPHB4 5400 CaMK4 >10000 PKACα >10000 
FLT4 16 MLK1_Cascade 5400 CDK2/CycA2 >10000 PKCα >10000 
KDR 16 EGFR 9000 CDK2/CycE1 >10000 PKD2 >10000 
LYNa 36 ALK >10000 CDK4/CycD3 >10000 PLK1 >10000 
PDGFRβ 39 AXL >10000 CDK6/CycD3 >10000 PRKX >10000 
LYNb 46 EPHB3 >10000 CHK1 >10000 ROCK2 >10000 
YES 75 FAK >10000 CK1ε >10000 SGK3 >10000 
FGR 200 FLT3 >10000 COT_Cascade >10000 TSSK1 >10000 
KIT 240 HER2 >10000 DAPK1 >10000 PIK3CA/PIK3R1 >10000 
ABL 250 IGF1R >10000 DYRK1B >10000   
LCK 290 KIT(V654A) >10000 
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Supplementary Table S2 
IC50 values for growth inhibition of various cancer cell lines by E7090. 
Cell line IC50 (nmol/L) 
Incubation 
time 
(days) 
Cell line IC50 (nmol/L) 
Incubation 
time 
(days) 
MFM223 2.0 3 T47D 1900 3 
MDA-MB-134 2.0 13 PC9 2000 6 
NCI-H1581 2.2 6 MKN-74 2100 3 
HSC-39 2.5 3 SNU-5 2200 3 
SNU-16 3.0 3 NCI-H2444 2300 6 
KATO-III 3.7 3 DMS454 2500 6 
KG-1a 4.0 3 CORL88 2800 6 
KMS-11 8.0 6 NCI-H1703 3100 6 
MFE-280 14 3 HCC827 3300 6 
A427 15 6 MKN-45 3400 3 
RT4 16 3 J82 3800 3 
RT112/84 31 3 CAMA-1 4500 3 
NCI-H520 41 6 NCI-H1650 4800 6 
DMS114 79 6 MKN-1 4900 3 
OPM-2 200 6 A549 5200 6 
BT474 200 3 Hs746T 5900 3 
ZR-75-1 530 3 MCF-7 5900 3 
DU4475 550 3 MKN-7 6900 3 
HT1197 1200 3 CAL120 >10000 3 
NCI-H226 1900 6    
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Supplementary Figure S1 
Kinome map of E7090. 
IC50 values of E7090 against wild-type kinases were used to create this kinome map. 
Illustration reproduced courtesy of Cell Signaling Technology, Inc. 
(www.cellsignal.com). 
33 
 
  
Supplementary Figure S2 
Inhibition of expression of proteins downstream of FGFR, including FRS2α, ERK, 
and AKT, in SNU-16 cells in vitro. 
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Supplementary Figure S3 
Western blot analysis of phospho-FGFR in SNU-16 tumors at the indicated times 
after treatment with the indicated concentrations of E7090. See also Figure 5A. 
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Supplementary Figure S4 
siRNA knockdown experiment in 4T1 cells indicating that growth of 4T1 breast 
cancer cells depends on FGFR2 and FGFR3. *, P < 0.05 compared with siControl-
treated cells (Dunnett test (vs siFgfr1, siFgfr2 and siFgfr3) or t-test (vs siFgfr4)). 
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Supplementary Figure S5 
Western blot analysis of FGFR1 in human lung cancer cell lines harboring FGFR1 
amplifications. 
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